A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.

Trial Details

NCT ID
NCT07218341
Phase
PHASE4
Sponsor
Eli Lilly and Company
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Pirtobrutinib
  • Idelalisib
Locations (sample)
  • Mobile, Alabama, United States|30.69436,-88.04305
  • Tucson, Arizona, United States|32.22174,-110.92648
  • Jacksonville, Florida, United States|30.33218,-81.65565
  • Coon Rapids, Minnesota, United States|45.11997,-93.28773
  • Ithaca, New York, United States|42.44063,-76.49661

Key Eligibility Criteria

  • Are actively participating in study J2N-MC-JZNN/LOXO-BTK-20020

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →